The use of botulinum toxin in head and face medicine: An interdisciplinary field by Laskawi, Rainer
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Head & Face Medicine
Open Access Review
The use of botulinum toxin in head and face medicine: An 
interdisciplinary field
Rainer Laskawi
Address: Universitäts-HNO-Klinik, Robert-Koch-Str. 40, D-37075 Göttingen, Germany
Email: Rainer Laskawi - rlaskaw@gwdg.de
Abstract
Background: In this review article different interdisciplinary relevant applications of botulinum
toxin type A (BTA) in the head and face region are demonstrated.
Patients with head and face disorders of different etiology often suffer from disorders concerning
their musculature (example: synkinesis in mimic muscles) or gland-secretion.
This leads to many problems and reduces their quality of life. The application of BTA can improve
movement disorders like blepharospasm, hemifacial spasm, synkinesis following defective healing of
the facial nerve, palatal tremor, severe bruxism, oromandibular dystonias hypertrophy of the
masseter muscle and disorders of the autonomous nerve system like hypersalivation,
hyperlacrimation, pathological sweating and intrinsic rhinitis.
Conclusion:  The application of botulinum toxin type A is a helpful and minimally invasive
treatment option to improve the quality of life in patients with head and face disorders of different
quality and etiology. Side effects are rare.
Review
Historical milestones, introduction
Justinus Kerner first described the symptoms of botulism
in detail [1]. Pierre van Ermengem isolated the microor-
ganism "bacillus botulinus" [2]. In 1979 A.B. Scott first
used botulinum toxin (BTA) therapeutically to correct
strabism injecting the toxin into external eye muscles [3].
The clinical use of BTA expanded during the last years (for
review see [4]). A lot of movement disorders and disorders
of the autonomous nerve system can be treated with this
option (see Table 1) and the head and neck region is an
interdisciplinary focus in this field. BTA prevents the
release of acetylcholine (ACHE) in synapses. ACHE acts as
a neurotransmitter for the innervation of muscles and dif-
ferent gland tissues. Blocking the release of ACHE leads to
a reduction of pathological movement of muscles and
secretion of glands in the head and neck area increasing
the quality of life for patients. In this connection the fol-
lowing pathological states of high interdisciplinary rele-
vance are focused in this article:
1. movement disorders of the facial nerve (blepharos-
pasm, hemifacial spasm, facial nerve palsy, synkinesis fol-
lowing defective healing of the facial nerve, aesthetic
applications, posttraumatic wound healing preventing
excessive scaring),
2. hypersalivation of different etiologies,
3. hyperlacrimation,
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4. gustatory sweating and
5. intrinsic or allergic rhinitis.
Movement Disorders
Mimic musculature
Facial nerve paralysis, synkinesis following defective heal-
ing of the facial nerve, hemifacial spasm, blepharospasm,
aesthetic applications, prevention of scar formation
Classical indications to be treated with BTA are the treat-
ment of patients suffering from a blepharospasm or a hemi-
facial spasm. Patients with a blepharospasm suffer from
repetetive cramps of the orbicularis oculi muscles leading
to eye closure. Patients suffering from a hemifacial spasm
experience repetetive tonic-clonic cramps of one half of
the mimic musculature (example see Fig 1). BTA is suited
to treat these diseases by injecting the substance into cer-
tain muscle depending on the clinical picture. Doses vary
from 1.25 to 5 units Botox® per injection point.
BTA is also helpful in other disorders of the mimic mus-
culature. In some cases a facial nerve paralysis leads to an
affection of the cornea with severe problems like a "kera-
titis e lagophthalmo". In such cases an injection into the
levator palpebrae muscle can close the eye for some time
to protect the cornea [5]. We use dosages of 5–10 units
Botox®, the injection is done subcutaneously in the mid-
dle of the upper lid. After about 3–4 months the eye
"opens" again and that is usually referring to the regener-
ation time of the paralysis.
In addition the esthetic outcome of a paralysis of the mar-
ginal branch of the facial nerve can be improved by inject-
ing 2.5–5 units Botox® into the depressor labii muscle of
the normal side [6].
Synkinesis are a non-avoidable sequelae following recon-
struction of the facial nerve in patients suffering from
malignant tumors of the parotid gland. Synkinesis are
characterized by synchronous but not intended move-
ments of certain areas of mimic muscles becoming mostly
evident during spontaneous movements of the face based
on emotional expressions. Mass movements can be
reduced using BTA. This options has been described first
by our group [7-9].
We normally inject BTA using 6 injection-points around
the eye to reduce foreign movements of the orbicularis
oculi muscle (see Fig 2). The complete injection design
and the total dosage depend on the extent of mass move-
ments and may vary from patient to patient. We normally
use dosages from 1.25–5 units Botox® on each injection
point. Side effects are very rare ; the reason for that could
be that lower dosages are necessary to treat synkinesis
Left side of the picture: patient with hemifacial spasm on the  right side of the face Figure 1
Left side of the picture: patient with hemifacial 
spasm on the right side of the face. He suffers from typ-
ical tonic-clonic cramps of the mimic muscles including the 
frontalis muscle and the platysma. Following BTA injections 
the face is relaxed and the frequency of tonic-clonic cramps 
is clearly reduced.
Table 1: Diseases treated with botulinum toxin type A in head and face medicine with high interdisciplinary relevance
Movement Disorders Disorders of the Autonomous Nerve System
Facial nerve paralysis Hypersalivation, Sialorrhea
Hemifacial spasm Gustatory sweating, Frey's syndrome
Blepharospasm, Meige-Syndrom Intrinsic rhinitis
Synkinesis following defective healing of the facial nerve Hyperlacrimation, Tearing
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compared to other facial dyskinesis like hemifacial spasm
or blepharospam.
Synkinesis of the platysma  are of special interest. We
focused on this problem and found an acceptable
decrease of complaints in treated patients [10,11].
Another interesting indication is the intraoperative appli-
cation of BTA during the surgical supply of fresh wounds
of the face. It has been demonstrated that weakening of
face muscles neighbouring facial wounds leads to a better
aesthetic outcome. The reason may be that after the
immobilization of the treated muscles the borders of fresh
wounds better adapt without muscular tension leading to
excellent aesthetic results [12].
The application of BTA to improve the aesthetic state of the
face is another wide field [13]. Periocular and many other
types of wrinkles are in the focus here (example see Fig 3).
For all facial applications the duration of the effect nor-
mally begins within 3–5 days and amounts 3–4 months.
Then the treatment has to be repeated. Side effects like a
ptosis (Fig 4), a "keratitis e lagophthalmo" or tearing are
rare.
An important, increasing field of application is the use of
BTA in different pain syndromes, especially in patients suf-
fering from tension headache, migraine and chronic daily
headache (for review see [14,15]).
Patient after BTA treatment of hyperlacrimation on both  sides (injection into lacrimal glands) Figure 4
Patient after BTA treatment of hyperlacrimation on 
both sides (injection into lacrimal glands). On the left 
side (left eye) a mild ptosis occurred. One can see the differ-
ence in the width of the palpebral fissure. The ptosis disap-
peared within 6 weeks.
Typical injection points for pathological movements of mimic  muscles Figure 2
Typical injection points for pathological movements 
of mimic muscles. The dose for each ponit may vary from 
1.25 units to 5 units Botox®. The number and locations of 
points depend on the individual character of the disorder in 
each single patient.
Effect of BTA on platysma wrinkles: left side: before BTA  treatment ; right side: after BTA treatment Figure 3
Effect of BTA on platysma wrinkles: left side: before 
BTA treatment ; right side: after BTA treatment. 
The skin of the neck region is apparently brightened.Head & Face Medicine 2008, 4:5 http://www.head-face-med.com/content/4/1/5
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Palatal tremor
Repetitive dystonic contractions of the muscles of the soft
palate (palatoglossus  and  palatopharyngeus  muscles,  salp-
ingopharyngeus, tensor and levator veli palatini muscles) lead
to a rhythmic elevation of the soft palate [16]. This can
cause speech and also swallowing disorders due to a velo-
pharyngeal insufficiency. Most patients suffering from
palatal tremor complain of "ear clicking". This rhythmic
tinnitus is caused by a repetitive opening and closure of
the orifice of the Eustachian tube. A particular sequelae of
pathological movements of soft palate muscles is the syn-
drome of a "patulous Eustachian tube" [17]. These
patients suffer from "autophonia" caused by an open Eus-
tachian tube due to the increased muscle tension of the
paratubal muscles (salpingopharyngeus, tensor and levator
veli palatini muscles).
In a first treatment session, the application of five units of
Botox® (uni- or bilaterally) into the soft palate is adequate
in most cases. If necessary, this can be increased to two
times 15 units of Botox®. The application is normally per-
formed transorally (transpalatinal or via postrhinoscopy)
under endoscopic control. To optimise the detection of
the target muscle, injection under electromyographic con-
trol is recommended. To avoid side effects such as iatro-
genic velopharyngeal insufficiency the treatment should
be started with low doses as described above.
Hyperactivity of jaw muscles
Oromandibular dystonia (OMD)
In patients with an OMD tongue prostrusions and abnor-
mal movements of the jaw are dominant feature of the
clinical picture (Fig 5) [18]. That may result in severe
symptoms for the patient like dysarthria and dysphagia.
An exact inspection, palpation and electromyographic
investigations are suited as diagnostic tools.
Depending of the kind of movement disorder, botulinun
toxin injections into the floor of the mouth, the extrinsic
tongue muscles and different jaw muscles have to be done
to improve the clinical picture. We avoid injections into
intinsic tongue muscles because weakening these muscles
may result into relevant side effects like swallowing disor-
ders, speech problems and problems of jawing.
Different approaches for injections are described like the
external and internal approach of the pterygoideus medi-
alis muscle as an example.
In the treatment of OMD, we use doses up to 50 units
Botox®.
Severe Bruxism [19]
If severe bruxisms does not improve after conventional
therapeutic measures, additional injections with botuli-
num toxin may improve the clinical picture. Injections
have to be done into the masseter and temporalis muscles
; doses up to 60 units Botox® per muscle are described. The
treatment can be performed using electromyography.
Hypertrophy of the masseter muscle
Hypertrophy of the masseter muscle leads to a difference
in the symmetry of the face [20].
The injection can be performed transoral or from outside.
In the literature, injections up to 50 units Botox® into each
masseter muscle are recommended.
Further indications
BTA also is used in patients with a fracture of the jaw for
immobilisation of the jaw, in patients with a jaw luxation
caused by a hyperactivity of the lateral pterygoid muscle
and in patients with a lockjaw.
Autonomous Nerve System
Hypersalivation
Hypersalivation is of high relevance for patients suffering
from different diseases (see Fig 6) [21,22]. Some patients
of this group are not able to swallow their saliva because
of a stenosis of the upper esophagus sphincter region
caused by scar formation after a tumor resection. In other
patients the sensory control of the entrance of the larynx
is reduced and therefore saliva may pass the larynx and
reach the trachea and the bronchus. That leads to perma-
nent aspiration and aspiration pneumonia. In a third
group of patients problems of the wound healing process
after extended surgery exist, like fistulas following larynge-
Patient with OMD: Pathologic movements of the mandible  are evident, patients use so called "gestes antagonistiques" to  break the dystonic activity of the jaw muscles Figure 5
Patient with OMD: Pathologic movements of the 
mandible are evident, patients use so called "gestes 
antagonistiques" to break the dystonic activity of the 
jaw muscles.Head & Face Medicine 2008, 4:5 http://www.head-face-med.com/content/4/1/5
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ctomies. In these cases saliva is a very aggressive agens pre-
venting a normal healing process. In addition, different
neurological disorders include hypersalivation as a very
serious symptom.
Based on our expanded experiences literature, we prefer in
our patients the ultra-sound-guided injection into the
parotid and submandibular gland on each side. We inject
into the parotid gland 22.5 units Botox® on each side, dis-
tributed on 3 points. The submandibular glands are
treated by a ultrasound-guided one or 2-point injection of
a total of 15 units Botox® per gland. It has been shown by
objective datas in a lot of papers that BTA injections are
effective in reducing the saliva flow, accompanied by very
few side effects.
Gustatory sweating, sweating of the face
Gustatory sweating is a common sequelae following
parotid gland surgery [23-28]. The treatment of gustatory
sweating with BTA has been described first by our group
in 1994 (first treated patient December 1993 [23,27]) and
became the first line treatment option in these patients.
To get an optimal outcome, we recommend marking of
the sweating area by Minor's test and then dividing the
sweating area in "boxes" using a waterproof pen. The
injections are done intracutaneously (see Fig 7).
The effectiveness of BTA treatment in patients with gusta-
tory sweating has been confirmed by a lot of other
authors. Some patients report a benefit after BTA-injection
already at the same day and interestingly, the positive
effect remains much longer than in patients with move-
Patient with extensive hypersalivation (drooling): he is not  able to swallow and so looses the saliva out of the mouth Figure 6
Patient with extensive hypersalivation (drooling): he 
is not able to swallow and so looses the saliva out of 
the mouth. He suffered from a "herpes-encephalitis" some 
years ago in his childhood.
Patient with gustatory sweating following parotidectomy Figure 7
Patient with gustatory sweating following parotidectomy. The deep blue color demonstrates the sweating area (left 
side of picture). The sweating area is marked with a waterproof pen and subdivided in boxes (middle). Following intracutane-
ous BTA injections, which have to be done intracutaneously, the affected area is completely dry after gustatory stimulation like 
eating an apple (see right side of picture).Head & Face Medicine 2008, 4:5 http://www.head-face-med.com/content/4/1/5
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ment disorders [24]. Some patients reach several years of
a symptom free interval.
The treatment of hyperhidrosis of the head and/or the face
are based on the same principles as described for patients
with gustatory sweating. The doses which are reached for
each individual patient depend on the size of the sweating
area to be treated.
Hyperlacrimation, Tearing
Hyperlacrimation (example see Fig 8) can be caused by a
stenosis of the lacrimal duct, by misdirected secretory fib-
ers following a degenerative paresis of the facial nerve
(crocodile tears) or after a mechanical irritation of the cor-
nea (in patients with a lagophthalmus). The application
of BTA is a helpful tool to reduce pathological tearing in
these patients in order to reach normal levels of tear liquid
production [29-31]. We inject 5–10 units Botox® into the
pars palpebralis of the lacrimal gland (technique see Fig
9). None of our patients suffered from a "dry eye" after
BTA treatment of the lacrimal gland.
Intrinsic Rhinitis
In the last few years, the application of Botulinum toxin
type A in patients with intrinsic or allergic rhinitis has
been described [32-34]. In experimants the existence of
apoptosis of nasal glands has been demonstrated [33].
The main symptom in patients suffering from these dis-
Patient suffering from a myoepithelial carcinoma of the right maxillary sinus Figure 8
Patient suffering from a myoepithelial carcinoma of the right maxillary sinus. After resection of the tumor the 
transport of tears into the nasal cavity was impossible so that the patient suffered from extensive hyperlacrimation (see left 
side of picture). Following BTA injection into the pars palpebralis of the right lacrimal gland, hyperlacrimation is reduced but no 
dry eye occurred (right side). This measure is suited to be done in patients with crocodile tears and any kind of stenosis of the 
lacrimal duct. It may be a good "interim treatment" before surgery and can be an alternative treatment when patients do not 
want to undergo surgery.
Application technique of BTA into the right lacrimal gland: A  little prominence under the upper lid, which is lifted, up  marks the needed direction of the cannula Figure 9
Application technique of BTA into the right lacrimal 
gland: A little prominence under the upper lid, which 
is lifted, up marks the needed direction of the can-
nula. Some millimeters after penetrating the tissue and lead-
ing the cannula into latero-dorsal direction, the pars 
palpebralis of the lacrimal gland is reached.Head & Face Medicine 2008, 4:5 http://www.head-face-med.com/content/4/1/5
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eases is extensive rhinorrhea with secretions dripping
from the nose.
There are two methods for applying BTA in these patients
(Fig 10): it can either be injected into the middle and
lower nasal turbinates [32], or it can be applied with a
sponge soaked in a solution of BTA (Fig. 10) [34].
For the injection we use 10 units of Botox® for each tur-
binate (middle and lower nasal turbinates).
With the other technique, the sponges are loaded with a
solution containing 40 units of Botox® and one is applied
on each side.
The positive effect of the injections has been demon-
strated in placebo-controlled studies [32]. Nasal secretion
is reduced for about 12 weeks (example see Fig 11). Side
effects such as epistaxis or nasal crusting were uncommon.
New developments and aspects
Some new developments in the use of BTA in head and
face medicine are to mention here (see [35]). BTA applica-
tion in patients suffering from tinnitus [36] or depressions
[37] have been treated with BTA. Further investigations
will show whether there is a real hope for clinical use of
BTA in these indications.
Conclusion
The application of botulinum toxin type A is a helpful and
minimally invasive treatment option in different func-
tional disorders improving the quality of life in patients
with head and face disorders of different etiology. Side
effects are rare.
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